Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
OBJECTIVE
To evaluate the efficacy of trilostane in treating dogs with pituitary-dependent hyperadrenocorticism.


METHODS
Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at University Veterinary Centre, Sydney from September 1999 to July 2001.


METHODS
Thirty dogs with pituitary-dependent hyperadrenocorticism treated with trilostane, a competitive inhibitor of 3beta-HSD, were monitored at days 10, 30 and 90 then 3-monthly by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and by client questionnaire.


RESULTS
Twenty-nine of 30 dogs were successfully treated with trilostane (median dose 16.7 mg/kg; range 5.3 to 50 mg/kg, administered once daily); one responded favourably but died of unrelated disease before full control was achieved.


CONCLUSIONS
Trilostane administration controlled pituitary-dependent hyperadrenocorticism in these dogs. It was safe, effective and free of side-effects at the doses used. Most dogs were initially quite sensitive to the drug for 10 to 30 days, then required higher doses until a prolonged phase of stable dose requirements occurred. Urinary corticoid:creatinine ratio was useful in assessing duration of drug effect. Some dogs treated for more than 2 years required reduction or temporary cessation of drug because of iatrogenic hypoadrenocorticism.
Braddock
J A
JA
Faculty of Veterinary Science, The University of Sydney, New South Wales, 2006.
Church
D B
DB
Robertson
I D
ID
Watson
A D J
AD
D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors*; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D015096:3-Hydroxysteroid Dehydrogenases; C009954:trilostane; D006854:Hydrocortisone